3-N-Butylphthalide
The risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.
Acenocoumarol
The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Tositumomab.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Tositumomab.
Alprostadil
The risk or severity of adverse effects can be increased when Alprostadil is combined with Tositumomab.
Advertisement
Anagrelide
The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Tositumomab.
Ancrod
The risk or severity of adverse effects can be increased when Ancrod is combined with Tositumomab.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Tositumomab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Tositumomab is combined with Anthrax immune globulin human.
Antithrombin III
The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Tositumomab.
Antithrombin III, Human
The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Tositumomab.
Apixaban
The risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.
Ardeparin
The risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.
Argatroban
The risk or severity of adverse effects can be increased when Argatroban is combined with Tositumomab.
Argatroban Anhydrous
The risk or severity of adverse effects can be increased when Argatroban is combined with Tositumomab.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tositumomab.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Bacillus calmette-guerin substrain tice live antigen.
Becaplermin
The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Tositumomab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Tositumomab.
Bivalirudin
The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.
Cangrelor
The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.
Certoparin
The risk or severity of adverse effects can be increased when Certoparin is combined with Tositumomab.
Cilostazol
The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.
Citric Acid
The risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.
Citric Acid, Anhydrous
The risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.
Clopidogrel
The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.
Clozapine
The risk or severity of adverse effects can be increased when Tositumomab is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Tositumomab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Tositumomab.
Dabigatran Etexilate
The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.
Dalteparin
The risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab.
Danaparoid
The risk or severity of adverse effects can be increased when Danaparoid is combined with Tositumomab.
Defibrotide
The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.
Desirudin
The risk or severity of adverse effects can be increased when Desirudin is combined with Tositumomab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Tositumomab.
Dextran
The risk or severity of adverse effects can be increased when Dextran is combined with Tositumomab.
Dicumarol
The risk or severity of adverse effects can be increased when Dicoumarol is combined with Tositumomab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Tositumomab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Tositumomab.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tositumomab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.
Edetic Acid
The risk or severity of adverse effects can be increased when Edetic Acid is combined with Tositumomab.
Edoxaban
The risk or severity of adverse effects can be increased when Edoxaban is combined with Tositumomab.
Enoxaparin
The risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.
Enoxaparin sodium
The risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.
Epinastine
The risk or severity of adverse effects can be increased when Epinastine is combined with Tositumomab.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.
Eptifibatide
The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.
Ethylenediaminetetraacetate
The risk or severity of adverse effects can be increased when Edetic Acid is combined with Tositumomab.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Tositumomab.
Fingolimod
Tositumomab may increase the immunosuppressive activities of Fingolimod.
Fluindione
The risk or severity of adverse effects can be increased when Fluindione is combined with Tositumomab.
Fondaparinux sodium
The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Tositumomab.
Heparin
The risk or severity of adverse effects can be increased when Heparin is combined with Tositumomab.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Tositumomab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Tositumomab is combined with Hepatitis B Vaccine (Recombinant).
Hydroxytyrosol
The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.
Icosapent Ethyl
The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.
Ifenprodil
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tositumomab.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.
Ketanserin
The risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.
Leflunomide
The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.
Lepirudin
The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.
Lipegfilgrastim
Tositumomab may increase the myelosuppressive activities of Lipegfilgrastim.
Milrinone
The risk or severity of adverse effects can be increased when Milrinone is combined with Tositumomab.
Nadroparin
The risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.
Natalizumab
The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Tositumomab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Tositumomab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tositumomab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.
Pentaerythritol Tetranitrate
The risk or severity of adverse effects can be increased when Pentaerythritol Tetranitrate is combined with Tositumomab.
Pentosan Polysulfate
The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.
Pentoxifylline
The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.
Phenindione
The risk or severity of adverse effects can be increased when Phenindione is combined with Tositumomab.
Phenprocoumon
The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Tositumomab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.
Potassium Citrate
The risk or severity of adverse effects can be increased when Potassium Citrate is combined with Tositumomab.
Prasugrel
The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Tositumomab.
protein C, human
The risk or severity of adverse effects can be increased when Protein C is combined with Tositumomab.
protein S, human
The risk or severity of adverse effects can be increased when Protein S human is combined with Tositumomab.
Protocatechualdehyde
The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Tositumomab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Tositumomab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Rabies virus inactivated antigen, A.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.
Reviparin
The risk or severity of adverse effects can be increased when Reviparin is combined with Tositumomab.
Reviparin sodium
The risk or severity of adverse effects can be increased when Reviparin is combined with Tositumomab.
Rivaroxaban
The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Tositumomab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Tositumomab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Tositumomab is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Tositumomab is combined with Salmonella typhi ty21a live antigen.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.
Sodium Citrate
The risk or severity of adverse effects can be increased when Sodium Citrate is combined with Tositumomab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Tositumomab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Tositumomab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Ticagrelor
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.
Ticlopidine
The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.
Tirofiban
The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.
Tofacitinib
Tositumomab may increase the immunosuppressive activities of Tofacitinib.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.
Trapidil
The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Tositumomab.
Triflusal
The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.
Trisodium Citrate Anhydrous
The risk or severity of adverse effects can be increased when Sodium Citrate is combined with Tositumomab.
Troxerutin
The risk or severity of adverse effects can be increased when Troxerutin is combined with Tositumomab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Tositumomab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vorapaxar
The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.
Warfarin
The risk or severity of adverse effects can be increased when Warfarin is combined with Tositumomab.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Tositumomab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Tositumomab is combined with Yellow Fever Vaccine.
